68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors

Recruiting now

Conditions studied: Neuroendocrine Tumors (NET)

In brief

To determine if 68Ga-HA-DOTATATE PET/CT imaging is effective at diagnosing somatostatin positive tumors compared to conventional imaging \[including CT, MRI, 111 In-pentetreotide Scans, 18F-FDG PET/CT, as available\]

Key facts

Study ID

NCT05673031

Run by

Alberta Health services

People needed

500

Starts

2023-02-01

Expected to finish

2027-01-01

Last updated by the study team

2023-01-05

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female. If female of child-bearing potential and outside of the window of 10 days since the last menstrual period, a negative pregnancy test will be required.
• Age greater than or equal to 18 years.
• Able and willing to follow instructions and comply with the protocol.
• Provide written informed consent prior to participation in the study.
• Clinically suspected (patients presenting with symptom(s) suggestive of carcinoid syndrome or biochemically suggestive of Neuroendocrine Tumor) or Biopsy proven Neuroendocrine Tumor

You may not qualify if…

• Nursing or pregnant females.
• Age less than 18 years.
• Surgery in the area of interest within the preceding 2 months.

Where it is running

• Foothills Medical Center 1403 29 St NW — Calgary, Alberta, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.